Sean Nolan is the current Chief Executive Officer of Taysha Gene Therapies, Inc., a company devoted to gene therapy advancements. He took over the role on December 16, 2022, following the resignation of his predecessor. With experience in executive roles,...

Sean Nolan is the current Chief Executive Officer of Taysha Gene Therapies, Inc., a company devoted to gene therapy advancements. He took over the role on December 16, 2022, following the resignation of his predecessor. With experience in executive roles, Nolan previously led AveXis, a gene therapy company acquired by Novartis. He is also the President of Nolan Capital, an investment firm, and brings a wealth of expertise from his board positions in other companies. In 2023, his focus shifted towards cash compensation, with a total salary of $600,000. Interestingly, Nolan received no bonuses or stock options in his first year, a reflection of his recent appointment. He does have a substantial number of stock options set to vest starting December 2023. Nolan's contract includes a significant severance package, showing that the company plans to invest in his leadership. His wealth of experience in navigating the biotechnology landscape underlines his strategic approach in steering Taysha’s mission forward.